Clinical Trials
19 trialsNCT02122172 2025-04-25
Afatinib in Advanced Refractory Urothelial Cancer
University of Chicago
Phase 2 Terminated
NCT03219333 2024-08-27
EV-201
Astellas Pharma Inc
Phase 2 Completed
NCT03513952 2024-07-26
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT03397394 2023-06-09
ATLAS
pharmaand GmbH
Phase 2 Terminated
NCT03617913 2023-01-06
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
Mayo Clinic
Phase 2 Completed
NCT02612194 2022-11-03
LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
Wake Forest University Health Sciences
Phase 2 Terminated
NCT01688999 2022-10-18
Cabozantinib for Advanced Urothelial Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00478361 2020-10-09
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00749892 2020-09-10
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02178241 2019-12-16
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01282463 2019-09-09
Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
Eli Lilly and Company
Phase 2 Completed
NCT01353222 2017-05-25
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Dendreon
Phase 2 Terminated
NCT00022633 2016-08-11
S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
SWOG Cancer Research Network
Phase 2 Terminated
NCT00397488 2016-01-25
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00407485 2014-10-20
VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium
National Cancer Institute (NCI)
Phase 2 Completed
NCT00112905 2014-05-30
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00471536 2014-05-30
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00045630 2013-05-27
S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium
SWOG Cancer Research Network
Phase 2 Completed
NCT00661609 2011-01-12
A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer
AstraZeneca
Phase 2 Completed